- Home
- DBVT vs ORIC Comparison
DBVT vs ORIC Comparison
Compare DBVT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBVT | ORIC |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | France | United States |
| Employees | 90 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBVT | ORIC |
|---|---|---|
| Price | $23.22 | $12.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $31.75 | $20.00 |
| AVG Volume (30 Days) | 175.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,151,000.00 | N/A |
| Revenue This Year | $65.50 | N/A |
| Revenue Next Year | $47.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.91 | $3.90 |
| 52 Week High | $26.19 | $14.93 |
Technical Indicators
Market Signals| Indicator | DBVT | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 52.48 |
| Support Level | $20.23 | $11.74 |
| Resistance Level | $23.47 | $12.66 |
| Average True Range (ATR) | 1.26 | 0.96 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 83.87 | 50.48 |
Price Performance
Historical ComparisonAbout DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.